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Background: The aim of this work was to determine the technical feasibility and safety of extended-field
radiotherapy (EF), performed by Helical TomoTherapy, in patients with positive pelvic and/or para-aortic nodes.
Dosimetric data were collected and acute and sub-acute toxicities of the upper abdominal organs at risk (OAR)
were evaluated.
Methods: Twenty-nine patients suitable for EF irradiation for local disease and/or nodal disease in the pelvic or
para-aortic area were treated. The prescription dose was 50.4/54 Gy (1.7-1.8 Gy/fraction) for prophylactic lymph
nodes (N-) and 60–70.5 Gy (2–2.35 Gy/fraction) for clinically evident gross disease (N+). Modulation factor (MF),
pitch and field width (FW) were chosen to optimize dose distribution and treatment duration. Dose values of PTVs
and OAR were analysed. The length of the treatment field, the N + and N- volumes, and treatment duration were
reported. To evaluate the safety of treatment, haematological, hepatic, renal and pancreatic functions were assessed
before, during and after treatment. The median follow-up time was 17.6 months (range: 6–22 months).
Results: The treatment was well tolerated and all patients but one completed treatment without interruption. Four
of the 29 patients experienced G3 haematological acute toxicity (13.8%), but no patient experienced sub-acute
grade G3 toxicity. Ten patients experienced G1 and three G2 acute gastrointestinal toxicity (nausea). No sub-acute
gastrointestinal or renal toxicity was observed. Only one (3.7%) patient had a persistent slight increase of pancreatic
enzymes and two (7.4%) patients a slight increase of hepatic enzymes six months after radiotherapy (G1 toxicity).
Conclusions: With our treatment design and dose regimen, we found that EF treatment by TomoTherapy could be
safely and effectively delivered with minimal acute and sub-acute toxicities in the upper abdomen area.
Keywords: Upper abdominal organ at risks, Helical TomoTherapy, Extended fields, ToxicityBackground
Extended volume irradiation for pelvis or lumbar-aortic
volumes, which may be required in some stages of prostate
or uterine cancer, presents difficulties when performed
with conventional conformal techniques [1].
Extended field (EF) irradiation was described in the
literature as early as the 1970s [2,3], but the use of* Correspondence: sara.bresciani@ircc.it
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reproduction in any medium, provided the orconventional radiotherapy techniques has been reported to
result in incomplete coverage of the target volume [4]. Fur-
thermore, standard techniques are also associated with
normal tissue complications. Indeed, with these tech-
niques, excessive amounts of organ at risk, such as small
bowel, have been included in the treatment fields, resulting
in increased gastrointestinal toxicity. In addition, a large
volume of bone marrow may be irradiated, leading to
hematologic count depression and untoward toxicity and
treatment interruption, especially in patients requiring con-
current chemotherapy [5]. Furthermore, dose escalation toal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of toxicity to abdominal critical structures, particularly in
upper abdomen, such as liver or kidneys [6].
Several reports have described the advantages of inten-
sity modulated radiation therapy (IMRT) over 3D-CRT
for EF treatments; the dosimetric advantage of IMRT
may improve the therapeutic outcome and reduce early
and late toxicity [7-9]. Compared with 3D-CRT and
IMRT by linac, Helical TomoTherapy (HT) allows EF to
be delivered without field junctions. HT also delivers a
more highly conformal dose distribution due to a greater
number of independent beam directions and facilitates ir-
radiation of large fields, with benefit especially for pa-
tients requiring para-aortic lymph node irradiation [10].
However, the potential clinical benefit of HT over IMRT
is still being investigated [11,12]. Furthermore, the body
of literature relating radiation doses to risk of abdominal
organs toxicity (stomach, small bowel, liver, kidneys, pan-
creas and spleen) is small compared with the amount of
data published on RT effects in some others organs, such
as rectum [13]. Indeed, although previous studies have
demonstrated that EF IMRT is safe and effective with a
low incidence of toxicities [7], very few studies have re-
ported relations of the dose in the upper abdominal or-
gans to normal tissue toxicity, especially in protocols
involving dose escalation to involved nodes.
The aim of this study was to perform a dosimetric and
toxicity analysis of HT plans in EF RT for pelvic and
para-aortic nodal regions with dose escalation to positive
nodes. We are reporting here our initial experience
for patients with locally advanced/recurrent prostate,
endometrial and cervical cancer by HT, focusing on
the technical feasibility of EF irradiation through the ana-
lysis of dose-volume histogram (DVH) parameters and
their correlation to toxicities, including assessments of
organ function by complete blood counts and the labora-
tory tests.
Methods
Between October 2010 and December 2012, 29 patients
were treated with extended-field IMRT (EF-IMRT) by
HT units. The series included 17 patients with nodal
recurrences of prostate cancer, 4 patients with very high-
risk prostate cancer, 5 patients with stage II-III of cer-
vical cancer and 3 patients with postoperative stage II-III
endometrial carcinoma. The intent of treatment was
radical in patients with prostate cancers, both primary
and recurrent, and in cervical cancer patients, and adju-
vant in endometrial cancers. Median age was 65.8 years
(range 40–84 years).
All patients with prostate cancer (both primary and
recurrent) received concomitant hormonal therapy. Pa-
tients affected by cervical cancer received concomitant
chemotherapy with weekly cisplatinum. The three patientswith operated endometrial cancer received adjuvant che-
motherapy with carboplatinum and taxol.
Before radiotherapy each patient underwent a CT-
simulation scan (BigBore Aquilion 16@Toshiba) with
3-mm slice thickness from the supra-diaphragmatic level
to 5 cm below the ischial tuberosities. Localization marks
were placed on anterior and lateral sides of the patients
between the fourth and the fifth lumbar vertebra. Patients
were positioned supine with arms up, immobilization sys-
tems used to fix extremities and pelvis were Harm Shuttle
and Pro-Step (Q-Fix, Avondale, PA, USA), respectively.
Two patients with recurrent prostatic tumour underwent
18F-choline PET/CT virtual simulation. All patients with
cervical and endometrial cancer received an 18F-FDG
PET/CT virtual simulation. PET images were retrieved on
a Pinnacle3 treatment planning system (Philips Health-
care, Madison, Wisconsin, USA) and matched with the
CT images for the tumour volume contouring.
Target volumes and normal tissues were contoured
on Pinnacle workstation, according to the International
Commission on Radiation Units and Measurements
(ICRU) Report No. 62 and 83 recommendations [14,15].
The gross tumor volume (GTV), the clinical target volume
(CTV) and lymph node regions (common, internal and ex-
ternal iliac, and para-aortic regions) were contoured. The
planning target volume (PTV) was created by expanding
uniformly the CTV volumes in order to account for organ
motion and setup uncertainty: for prostate gland and sem-
inal vesicles, an anisotropic margin of 0.8 cm was added,
except for posteriorly where the margin was 0.6 cm. For
pelvic and para-aortic prophylactic nodes we added an
isotropic margin of 0.5 cm in all directions and for in-
volved nodes we added a tailored margin of up to 0.7 cm,
depending on proximity of small bowel or other critical
structures.
The rectum (defined from the sigmoid flexure to the
anus), sigma-colon, bladder and femoral heads, anus,
penile bulb, also small bowel (defined as intestinal cavity),
kidneys, pancreas, stomach, spleen, ureter, and the liver
were contoured on all patients for dosimetric and toxicity
evaluation. The small bowel portion inside PTV N- and
PTV N+was designated as “small bowel in” and was used
during optimization to achieve sufficient dose sparing of
the OAR.
The dose prescription for the EF-IMRT plans was 51–
54 Gy (1.7-1.8 Gy/fraction) for prophylactic lymph nodes
and 60/66 Gy (2–2.2 Gy/fraction) to PTV N + in the
para-aortic or pelvis chain, with a simultaneous integrated
boost (SMART technique irradiation). Lymph nodes dose
prescription depended on their localization: for PTV N+
lymph nodes that overlap the small bowel loops, the dose
prescription was 60 Gy (Figure 1).
CT data-sets and structures were transferred from
Pinnacle3 to the Tomotherapy Planning Workstation.
Figure 1 Example of extended field irradiation for cervical carcinoma. Isodose distribution for sagittal and coronal projections through the
patient’s midline is provided (red = 66Gy, pink = 54Gy, blue = 51Gy).
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calculation process are pitch, field width (FW) and
modulation factor (MF). By increasing the FW and redu-
cing the pitch and MF we can significantly reduce the
treatment time. For optimum dose conformality, small
FW and pitch and high MF should be employed, at the
expense of longer treatment times. In clinical practice,
the selection of FW, pitch and MF represents a com-
promise between excessively long treatment times (with
highly conformal delivery) and shorter treatment times
(with some loss of conformality ). Prior to optimization,
dose volume constraints, overlap, importance and penalty
factors for target and critical structures were assigned.
Accuracy of setup was verified daily by megavoltage CT
imaging (MVCT).
Patients were evaluated weekly during the course of
radiotherapy to assess acute toxicity. Acute toxicity was
defined as those occurring within 90 days of competition
of radiation therapy. Hematological, hepatic, renal and
pancreatic functions were evaluated by complete blood
count and laboratory tests before, during and after treat-
ment. Toxicities were graded according to the National
Institute Common Toxicity Criteria for Adverse Events
(CTCAE), version 3.0 scale.
Dose-volume histograms (DVHs) of the PTVs and the
critical normal structures were analysed. For PTVs, we
evaluated the average dose and the dose delivered to
95% of Volume (D95%).
The length of the treatment field, the volume (cc) of
the positive lymph nodes (N+) and prophylactic lymph
nodes (N-) were also evaluated. For OAR, the mean and
maximum dose of small bowel, pancreas, spleen, stom-
ach, kidneys and liver were examined. V45 of small bowel
was registered according to QUANTEC recommenda-
tions [12]. Our dose-volume constraints are summarizedin Table 1. Finally, when we adopt a new technology
careful considerations are necessary, particularly in a
field where the incidence of late second cancers is be-
coming a dominant concern. For this reason and for a
better assessment of the safety of the EF irradiation by
TomoTherapy we evaluated also the low dose distribu-
tion deposited in the critical structures, in terms of
V5Gy, V10Gy, V15Gy of the body [16].
The correlation between gastrointestinal, liver and pan-
creatic toxicities and dosimetric parameters were investi-
gated in univariate analysis (logistic regression).
Results
In most cases, plan parameter values used for these treat-
ments were FW= 2.5 cm, pitch = 0.287 cm and MF= 2.2.
In two cases we used a FW of 5 cm to reduce treatment
time. The value of these parameters were chosen in order
to produce a treatment that could be delivered in a reason-
able length of time (<15 min). In one re-treatment case we
used a FW of 1.05 cm because the new target was just su-
perior to a previously treated PTV and the smaller field has
a smaller penumbra in longitudinal direction. The median
actual MF was 1.8 (range: 1.3-2.6). The average length of
treatment was 32.5 cm. Dose calculation grid was always
set to fine mode. Median treatment time was 660 sec
(range: 306–912 sec). The overall pretreatment daily setup
procedure with control of positioning accuracy was per-
formed in 890 sec (range: 530–1050 sec).
Each planning target volume was covered by 95% of the
prescribed dose and a steep dose gradient was obtained in
the direction of the abdominal OARs. Excellent PTV
coverage was obtained: in general, the mean value of
D95% for PTVs of primary targets was 96.5%, ranging be-
tween 94% and 98%. Mean absolute dose and D95% were
65.3 ± 3.5 Gy and 63.7 ± 3.4 Gy to PTVN+, 54.5 ± 2.1 Gy
Table 1 Normal tissue tolerance
Critical structure Volume Dose/volume Toxicity rate Toxicity endpoint
Liver Mean <30-32 Gy <5% RILD (in normal liver function)
Kidney, bilateral Mean <15-18 Gy <5% Clinical dysfunction
Kidney, bilateral Mean <28 Gy <50% Clinical dysfunction
Kidney, bilateral V12 <55% <5% Clinical dysfunction
Kidney, bilateral V20 <32% <5% Clinical dysfunction
Kidney, bilateral V23 <30% <5% Clinical dysfunction
Kidney, bilateral V28 <20% <5% Clinical dysfunction
Stomach D100 <45 Gy <7% Ulceration
Small bowel (peritoneal cavity) V45 <195 cc <10% Grade 3+ toxicity
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1–6 positive pelvic and/or lumbar-aortic nodes simultan-
eously, with a mean volume of 76.6 ± 48.3 cc. Mean vol-
umes of irradiated prophylactic nodes was 770.6 ± 307.1 cc.
Mean doses to organs at risk are shown in Table 2.
The mean volume of small bowel that received more
than 45 Gy (V45) was 157 ± 83 cc (4.3 ± 3.7%). Maximum
dose to small bowel was less than 60 Gy and the mean
V55 was 1.8 ± 2.2cc (0.4 ± 0.5%). No patients failed to
meet QUANTEC published dose objectives for the rec-
tum, bladder, femoral heads, liver, kidney and spinal cord
[17]. Only two patients treated for postoperative endomet-
rial cancer exceeded the QUANTEC constraint for the in-
testinal cavity with a V45 > 230 cc instead of < 195 cc. The
mean DVH curves for liver, pancreas, left and right kidney,
stomach and small bowel are plotted in Figure 2.
The mean volume ± standard deviation of body that
received more 5, 10 and 15 Gy were 22587 ± 4856 cc,
18109 ± 4344 cc and 12287 ± 3081, respectively.
Acute and sub-acute toxicity
The median follow-up time was 17.6 months (range: 6–
22 months). Overall the treatment was well tolerated:
all patients but one completed treatment without inter-
ruption. One patient who received concurrent chemo-
therapy for cervical carcinoma required a break of 6
days due to severe urinary infection. Of these 29 pa-
tients, 10 (34.5%) experienced G1 and 3 (10.3%) G2 acuteTable 2 Mean doses and standard deviations to organs
at risk
Organs at risk Dmean (Gy) Dmax (Gy)
Pancreas 28.1 ± 6.4 49.9 ± 9.2
Spleen 10.3 ± 6.5 25.8 ± 15.7
Stomach 16.1 ± 5.6 46.3 ± 10.2
Liver 10.0 ± 9.6 49.2 ± 11.8
Right kidney 11.8 ± 3.1 27.4 ± 7.3
Left kidney 13.5 ± 7.5 35.6 ± 12.9gastrointestinal toxicity (nausea). Acute hematological tox-
icity was the following: G1 in 7 patients (24.1%), G2 in 4
patients (13.8%; 2 of these patients received chemotherapy,
one concurrently, and 2 received only hormonal therapy),
G3 in 4 patients (13.8%; all of whom received chemo-
therapy, 3 concurrently). In 3 (10.3%) patients we observed
an early slight increase of pancreatic enzyme (G1 acute
toxicity) and in 5 (17.2%) patients an early slight increase
of hepatic enzymes (G1 acute toxicity). No acute renal tox-
icity was observed. Table 3 summarizes mean doses and
standard deviations to organs at risk for patients with tox-
icity. Table 4 summarizes acute toxicity as a function of the
patient, disease, and treatment characteristics (i.e. history
of prior RT or surgery).
About sub-acute toxicity, no gastrointestinal or renal
toxicity was observed. G1 hematological toxicity occurred
in 1 (3.5%) patient and G2 in 2 (6.9%) patients. Only one
(3.5%) patient had a persistent slight increase of pancreatic
enzyme and 2 (6.9%) patients a slight increase of hepatic
enzymes six months after radiotherapy (G1 toxicity). All
patients with hematological, pancreatic and hepatic toxicity
received chemotherapy during radiation treatment. Acute
and sub-acute toxicities are summarized in Table 5.
Performing univariate analysis, we did not find any
correlations between V45 of small bowel and gastrointes-
tinal toxicity (p = 0.28), between liver toxicity (increase of
amylases value) and Dmean (p = 0.55) and Dmax (p = 0.54).
Univariate analysis showed a statistically significant as-
sociation (p = 0.029) between the development low sub-
acute pancreatic toxicity and Dmax, but no statistically
significant association with Dmean (p = 0.11). In the case
of acute toxicity, we did not find correlation for both
Dmax (p = 0.06) and Dmean (p = 0.34).
In more details, about pancreatic toxicity, the only one
patient that experienced G1 acute and late pancreatic
toxicity showed a pancreatic dose greater than 60 Gy
(D1cc = 67.8 Gy). The DVH of this patient is reported in
Figure 3. The values of DVH for pancreas were evalu-
ated by comparing the mean relative volumes at selected
doses values between the patient with toxicity and the
Figure 2 Average DVHs of the patients. The average DVHs of the pancreas, stomach, liver, kidneys and small bowel (intestinal cavity).
Table 3 Mean doses and standard deviations to organs at risk for patients with toxicity
Organs at risk G1 acute/subacute G2 acute/subacute G3 acute/subacute
Pancreas
Dmean (Gy) 32.0 ± 8.2/37.8
/
Dmax (Gy) 61.7 ± 8.6/67.1 /
Liver
Dmean (Gy) 10.8 ± 3.1/11.6 ± 2.2
/
Dmax(Gy) 45.8 ± 12.5/54.4 ± 2.1 /
Small bowel V45(cc) 168 ± 59 130 ± 84 158
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Table 4 Acute toxicity as a function of patient and disease characteristics










total G0-G1 ≥G2 G0-G1 ≥G2 G0-G1 ≥G2 G0-G1 ≥G2 G0-G1 ≥G2
Total 29 26 3 21 8 29 0 29 0 29 0
Median age (y) 65.1 66.1 54 67.9 57.6 65.1 0 65.1 0 65.1 0
Primary prostate cancer 4 3 1 3 1 4 0 4 0 4 0
Nodal recurrence of prostate cancer 17 17 0 16 1 17 0 17 0 17 0
Postoperative endometrial cancer 3 3 0 1 2 3 0 3 0 3 0
Primary cervical cancer 5 3 2 1 4 5 0 5 0 5 0
History of abdominal surgery 15 15 0 12 3 15 0 15 0 15 0
History of prior RT 13 13 0 12 1 13 0 13 0 13 0
Paraaortic RT 10 10 0 9 1 10 0 10 0 10 0
Paraaortic + pelvic nodes RT 19 16 3 12 7 19 0 19 0 19 0
Intracavitary brachytherapy 5 5 0 1 4 5 0 5 0 5 0
Concurrent chemotherapy 7 6 1 2 5 7 0 7 0 7 0
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t-tests were performed at each 10 Gy dose level; no
p values reached statistical significance (p > 0.05), until
60 Gy. The only patient whose pancreas dose exceeded
60 Gy was the patient with toxicity.
With a mean follow up of 17.6 months the outcome of
the treated patients is the following: all patients but one
(partial response) had a complete response in the irradi-
ated regions; at the moment 16 patients (55.2%) are liv-
ing without disease (NED); 12 patients (41.4%) are living
with disease (LWD) and 1 patient (3.5%) is died, for dis-
ease. No patients had loco-regional recurrences.
Discussion
In the present study we analyzed the feasibility and dos-
imetry for upper abdominal organs at risk of EF-IMRTTable 5 Acute and sub-acute toxicity












Renal 29 0treatments with HT. The safety of treatment was evalu-
ated in terms of acute and sub-acute toxicities. Dose vol-
ume constraints, laboratory tests and complete blood
count were the main focus of the evaluation.
Historically, anteroposterior-posteroanterior (AP-PA)
or 4-field techniques were used for EF, but the treatment
was not without significant toxicity (e.g., RTOG 7920
demonstrated grade 4 to 5 GI toxicity rates of 8% with
AP-PA EF-RT [17]). With standard RT techniques, dose
escalation to an extended field was limited by the nor-
mal tissue tolerances.
To reduce exposure of abdominal organs at risk, in the
past few years IMRT was adopted to irradiate extended
fields. Several studies have assessed to treatment of the
whole pelvis using IMRT (IM-WPRT), but relatively few
have addressed extended-field IMRT (EF-IMRT). Kiddade 2 Grade 3 Grade 4 Grade 5
3 0 0 0
4 4 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
2 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
Figure 3 DVH of the pancreas. The DVH of the pancreas of patient that experienced G1 pancreatic toxicities.
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among cervical cancer patients receiving IMRT, of whom
13% had EF-IMRT, significantly lower than the 10.7% rate
associated with conventional RT [18].
The general advantage of EF-IMRT irradiation on PTV
coverage and homogeneity has been well documented, but
few papers describe dose escalation in EF performed by
TomoTherapy [11]. To the best of our knowledge, the ad-
vantage of IMRT on normal tissue sparing, in particular
the organs of the upper abdomen, is only hypothesized and
not quantified. For exemple, Portelance et al. [7] described
the reduction of small bowel, rectum and kidney dose with
Linac-based IMRT vs conventional treatment. At a dose of
45 Gy, the percentage of small bowel receiving the pre-
scribed dose (45 Gy) with the IMRT technique varied
as a function of technique as follows: four fields (11.01 ±
5.67%); seven fields (15.05 ± 6.76%); nine fields (13.56 ±
5.30%). These percentages were all significantly lower than
those obtained with 2 AP-PA fields (35.28 ± 13.84%) and 4
box fields (34.24 ± 17.82%) (p < 0.05). Even though our
prescription dose was higher than 45 Gy, our dosimetric
result with TomoTherapy for the amount of small bowel
receiving 45 Gy was 4.3 ± 3.7%, lower than IMRT and on
average 87% lower than the AP-PA technique. As regards
dose homogeneity and target coverage, we obtained good
results with the EF-IMRT technique, without hot and cold
spot regions typical of the 3D treatments (no patient with
Dmax > 107%).
The results of our analysis are particularly striking
when considering the pancreas, liver and kidney, even if
is not possible to perform a comparison with literaturedata because of the absence, to our knowledge, of a simi-
lar analysis for these organs at risk. In one report, using
at least 45 Gy to the para-aortic nodes, no patients expe-
rienced acute grade ≥3 GI toxicity [7]. In a second study,
EF-IMRT with dose escalation to 55 to 60 Gy adminis-
tered to involved nodes along with concurrent cisplatin
resulted in G3 acute and late GI toxicity rates of 2.8%
and 5.6%, respectively.
As a whole, when considering the target coverage im-
provement, the OAR sparing capability and the ease of
execution and delivery time, the use of the EF-IMRT tech-
nique shows a definite improvement in performance and
safety. Our dose escalation schedule did not increase acute
toxicity. We believe that clinical implementation of EF-
IMRT with Tomotherapy decreases the normal tissue com-
plications, especially when chemotherapy is added and
pelvis/para-aortic lymph nodes are grossly involved, and a
dose escalation protocol is required. On the other hand, a
controversial aspect to be considered, especially in young
patients, is the risk of induction of secondary malignancies
which may result from larger low dose tissue volumes with
TomoTherapy vs Linac-based [16].
In summary, our data show that, in the treatment of large
fields, normal tissue sparing with IMRT by TomoTherapy
allows very low acute and sub-acute toxicity. To date no
G3 sub-acute toxicity has been observed. Moreover we
confirm prior reports by showing that severe acute toxicity
(G3) was observed only in patients that received concomi-
tant chemotherapy. Given the simplicity of the EF-IMRT
technique performed with TomoTherapy and the large
PTVs considered, the obtained results are encouraging.
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With our treatment design and dose regimen, even with
dose escalation up to 66 Gy (2.2 Gy/fraction) to involved
nodes in para-aortic and pelvic nodal regions, we found
that EF IMRT by TomoTherapy could be delivered with
minimal acute and sub-acute toxicities in the upper ab-
domen area. Dosimetric analysis among our patient set
did not establish any specific dose-volume relationships
for GI and liver toxicities, but showed that high dose
(>60 Gy) could be correlated with pancreatic toxicity.
Our results indicated that EF-IMRT by HT seems to
be a safe treatment approach: therapy was well tolerated
and there were no sub-acute Grade 3 and 4 toxicities.
No patient died due to treatment toxicity. In our study,
no patient to date has exhibited any renal toxicity and
no patient has reported hepatic and/or pancreatic toxic-
ities greater than G1. Longer follow-up is required to
validate these favorable long-term toxicity findings.
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